



ELLE
Ovarian Cancer
Survivor

**LIFE DESERVES FEWER
INTERRUPTIONS**

AND MORE GOOD DAYS

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.